Pharming Group N.V. (LON:0QCO)

Market Cap	490.74M
Revenue (ttm)	213.19M
Net Income (ttm)	-13.30M
Shares Out	n/a
EPS (ttm)	-0.02
PE Ratio	n/a
Forward PE	n/a
Dividend	n/a
Ex-Dividend Date	n/a

Volume	42,790
Average Volume	115,272
Open	0.880
Previous Close	0.875
Day's Range	0.867 - 0.887
52-Week Range	0.538 - 1.008
Beta	0.70
RSI	52.34
Earnings Date	Apr 4, 2025

About Pharming Group

Pharming Group N.V., a biopharmaceutical company, develops and commercializes protein replacement therapies and precision medicines for the treatment of rare diseases in the United States, Europe, and internationally. The company offers RUCONEST, a recombinant C1 esterase inhibitor for the treatment of acute attacks in adult and adolescent patients with acute hereditary angioedema (HAE); and Joenja (leniolisib), an oral small molecule PI3Kẟ inhibitor for the treatment of activated phosphoinositide 3-kinase delta syndrome. It also develops OTL-1...

• Industry: Biological Products, Except Diagnostic Substances
• Founded: 1988
• Employees: 382
• Stock Exchange: London Stock Exchange
• Ticker Symbol: 0QCO

Financial Performance

Financial numbers in USD